September 12, 2024
MADRID — Amycretin, a dual pathway, oral weight loss drug, led to up to 13% body weight loss in participants with overweight or obesity according to […]
September 12, 2024
TOPLINE: MADRID — In children with a genetic susceptibility to type 1 diabetes (T1D), a higher consumption of oats, fruits, or rye may increase the risk […]
September 12, 2024
MADRID — Novo Nordisk’s investigational once-weekly combination of insulin icodec plus semaglutide (IcoSema) could benefit people with type 2 diabetes who don’t reach target glycemic goals […]
September 12, 2024
MADRID — A daily 8-hour eating window controls blood glucose whether followed early or late in the day by people at risk for type 2 diabetes, […]
September 12, 2024
TOPLINE: Diabetic neuropathy and retinopathy are associated with a higher risk for moderate/severe periodontitis. Dyslipidemia further increases this risk, highlighting the need for comprehensive management in […]
September 11, 2024
The glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide is the first in its class to show benefits in young children with obesity, according to results from the […]
September 11, 2024
TOPLINE: MRI-derived abdominal adipose tissue is linked to chronic musculoskeletal pain in multiple sites. The association is stronger in women, suggesting sex differences in fat distribution […]
September 11, 2024
MADRID, Spain — Eli Lilly’s investigational once-weekly basal insulin analog efsitora alfa continues to show noninferiority to once-daily insulin in people with type 2 diabetes. However, […]
September 11, 2024
TOPLINE: Elevated interleukin (IL) 6 levels are associated with an increased risk for obesity-related cancers in patients newly diagnosed with type 2 diabetes (T2D), potentially enabling […]